(AOF) – Poxel announces that as of June 30, 2023, its cash and cash equivalents amounted to 7.6 million euros compared to 13.1 million euros as of December 31, 2022. The biotech estimates that its resources will be sufficient to finance its operations and its investment needs until the end of the second quarter of 2025. It achieved a turnover of 955,000 euros for the six months ended June 30, 2023, compared to 83,000 euros at during the corresponding period in 2022.
Twymeeg’s sales in Japan for the last quarter (April-June) are up 23% compared to the previous quarter, and Sumitomo Pharma’s forecast for fiscal 2023 would represent a 90% increase compared to sales of the ‘last year. Poxel is actively seeking additional funding to initiate phase II proof of concept (POC) studies in adrenoleukodystrophy (ALD) and to continue the execution of its strategic plan in rare diseases.
© 2023 Agence Option Finance (AOF) – All rights reserved by AOF. AOF collects its data from the sources it considers the most reliable. However, the reader remains solely responsible for their interpretation and for the use of the information made available to them. Thus the reader must hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends with the buttons below.
